Levetiracetam Actavis

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

levetiracetam

Available from:

Actavis Group PTC ehf

ATC code:

N03AX14

INN (International Name):

levetiracetam

Therapeutic group:

Anti-epilettiċi,

Therapeutic area:

Epilessija

Therapeutic indications:

Levetiracetam Actavis huwa indikat bħala monotherapy fit-trattament ta ' b'sekwestru parzjali-iskoppjar bi jew mingħajr ġeneralizzazzjoni sekondarju fil-pazjenti minn 16-il sena ta ' l-età ma ġodda djanjostikat epilessija. Levetiracetam Actavis huwa indikat bħala terapija aġġuntiva:fil-kura ta 'aċċessjonijiet ta' bidu parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja f'adulti, tfal u trabi mill-età ta'xahar bl-epilessija;fit-trattament ta ' aċċessjonijiet mijokloniċi f'adulti u addoloxxenti minn 12 il-sena tal-minorenni b'epilessija mijoklonika;fit-trattament ta seizures tonic-clonic ġeneralizzati fl-adulti u addoloxxenti minn 12 il-sena b'epilessija ġeneralizzata idjopatika.

Product summary:

Revision: 19

Authorization status:

Awtorizzat

Authorization date:

2011-10-03

Patient Information leaflet

                                54
B. FULJETT TA’ TAGĦRIF
55
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
LEVETIRACETAM ACTAVIS 250 MG PILLOLI MIKSIJA B’RITA
LEVETIRACETAM ACTAVIS 500 MG PILLOLI MIKSIJA B’RITA
LEVETIRACETAM ACTAVIS 750 MG PILLOLI MIKSIJA B’RITA
LEVETIRACETAM ACTAVIS 1000MG PILLOLI MIKSIJA B’RITA
levetiracetam
AQRA DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU INTI JEW IT-TFAL TIEGĦEK
DIN IL-MEDIĊINA PERESS LI FIH
INFORMAZZJONI IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista jkollok bżonn terġa taqrah.
-
Jekk ikollok aktar mistoqsijiet, jekk jogħġbok staqsi lit-tabib jew
spiżjar jew l-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
jew l-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li m’huwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Levetiracetam Actavis u għalxiex jintuża
2.
X’għandek tkun taf qabel ma’ tieħu Levetiracetam Actavis
3.
Kif għandek tieħu Levetiracetam Actavis
4.
Effetti sekondarji possibbli
5.
Kif taħżen Levetiracetam Actavis
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU LEVETIRACETAM ACTAVIS U GЋALXIEX JINTUŻA
Levetiracetam hija mediċina għal kontra l-epilessija (użata biex
tittratta laċċessjonijiet f-epilessija).
Levetiracetam Actavis huwa wżat:
•
waħdu f' adulti u adolexxenti minn 16 il-sena b’epilessija li
għadha kif ġiet iddijanjostikata, fit-
trattament ta' ċertu forma ta’ epilessija. Epilessija hija
kundizzjoni fejn il-pazjenti jkollhom
aċċessjonijiet ripetuti. Levetiracetam huwa użat għall-forma ta’
epilessija li fiha l-aċċessjonijiet
inizjalment jaffettwaw naħa waħda biss tat-moħħ, imma wara dan
jistgħu jestendu għal erjas ikbar
fiż-żewġ naħat tal-moħħ (aċċessjoni li jibda parzjalment bi
jew mingħajr ġeneralizzazzjoni
sekondarja). Levet
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM TAL-PRODOTT MEDIĊINALI
Levetiracetam Actavis 250 mg pilloli miksija b'rita.
Levetiracetam Actavis 500 mg pilloli miksija b’rita.
Levetiracetam Actavis 750 mg pilloli miksija b’rita.
Levetiracetam Actavis 1000 mg pilloli miksija b’rita.
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Levetiracetam Actavis 250 mg pilloli miksija b’rita.
Kull pillola miksija b'rita fiha 250 mg levetiracetam.
Levetiracetam Actavis 500 mg pilloli miksija b’rita.
Kull pillola miksija b’rita fiha 500 mg levetiracetam.
Levetiracetam Actavis 750 mg pilloli miksija b’rita.
Kull pillola miksija b’rita fiha 750 mg levetiracetam.
Eċċipjent b’effett magħruf
Kull pillola miksija b’rita fiha 0.156 mg sunset yellow E110.
Levetiracetam Actavis 1000 mg pilloli miksija b’rita.
Kull pillola miksija b’rita fiha 750 mg levetiracetam.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b'rita (pillola).
Levetiracetam Actavis 250 mg pilloli miksija b'rita.
Ovali, blu ċar, 13.6 x 6.4 mm imnaqqxa b’ “L” fuq naħa u
“250” fuq naħa oħra.
Levetiracetam Actavis 500 mg pilloli miksija b’rita.
Ovali, safra, 17.1 x 8.1 mm imnaqqxa b’ “L” fuq naħa u
“500” fuq naħa oħra.
Levetiracetam Actavis 750 mg pilloli miksija b’rita.
Ovali, oranġjo, 19.0 x 9.3 mm imnaqqxa b’ “L” fuq naħa u
“750” fuq naħa oħra.
Levetiracetam Actavis 1000 mg pilloli miksija b’rita.
Ovali, bajda, 19.0 x 10.0 mm imnaqqxa b’ “L” fuq naħa u
“1000” fuq naħa oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Levetiracetam Actavis huwa indikat biex ikun użat bħala monoterapija
fit-trattament ta' aċċessjonijiet
tat-tip parzjali kemm meta jkun hemm, kif ukoll meta ma jkunx hemm
ġeneralizzazzjoni sekondarja f'
adulti u adolexxenti li għandhom minn 16 il-sena li għadhom kif ġew
dijanjostikati b’ epilessija.
Levetiracetam Actavis huwa indikat biex ikun użat bħala parti
mit-terapija
•
fit-trattament
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-06-2023
Public Assessment Report Public Assessment Report Bulgarian 07-09-2021
Patient Information leaflet Patient Information leaflet Spanish 22-06-2023
Public Assessment Report Public Assessment Report Spanish 07-09-2021
Patient Information leaflet Patient Information leaflet Czech 22-06-2023
Public Assessment Report Public Assessment Report Czech 07-09-2021
Patient Information leaflet Patient Information leaflet Danish 22-06-2023
Public Assessment Report Public Assessment Report Danish 07-09-2021
Patient Information leaflet Patient Information leaflet German 22-06-2023
Public Assessment Report Public Assessment Report German 07-09-2021
Patient Information leaflet Patient Information leaflet Estonian 22-06-2023
Public Assessment Report Public Assessment Report Estonian 07-09-2021
Patient Information leaflet Patient Information leaflet Greek 22-06-2023
Public Assessment Report Public Assessment Report Greek 07-09-2021
Patient Information leaflet Patient Information leaflet English 22-06-2023
Public Assessment Report Public Assessment Report English 07-09-2021
Patient Information leaflet Patient Information leaflet French 22-06-2023
Public Assessment Report Public Assessment Report French 07-09-2021
Patient Information leaflet Patient Information leaflet Italian 22-06-2023
Public Assessment Report Public Assessment Report Italian 07-09-2021
Patient Information leaflet Patient Information leaflet Latvian 22-06-2023
Public Assessment Report Public Assessment Report Latvian 07-09-2021
Patient Information leaflet Patient Information leaflet Lithuanian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-06-2023
Public Assessment Report Public Assessment Report Lithuanian 07-09-2021
Patient Information leaflet Patient Information leaflet Hungarian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 22-06-2023
Public Assessment Report Public Assessment Report Hungarian 07-09-2021
Patient Information leaflet Patient Information leaflet Dutch 22-06-2023
Public Assessment Report Public Assessment Report Dutch 07-09-2021
Patient Information leaflet Patient Information leaflet Polish 22-06-2023
Public Assessment Report Public Assessment Report Polish 07-09-2021
Patient Information leaflet Patient Information leaflet Portuguese 22-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 22-06-2023
Public Assessment Report Public Assessment Report Portuguese 07-09-2021
Patient Information leaflet Patient Information leaflet Romanian 22-06-2023
Public Assessment Report Public Assessment Report Romanian 07-09-2021
Patient Information leaflet Patient Information leaflet Slovak 22-06-2023
Public Assessment Report Public Assessment Report Slovak 07-09-2021
Patient Information leaflet Patient Information leaflet Slovenian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 22-06-2023
Public Assessment Report Public Assessment Report Slovenian 07-09-2021
Patient Information leaflet Patient Information leaflet Finnish 22-06-2023
Public Assessment Report Public Assessment Report Finnish 07-09-2021
Patient Information leaflet Patient Information leaflet Swedish 22-06-2023
Public Assessment Report Public Assessment Report Swedish 07-09-2021
Patient Information leaflet Patient Information leaflet Norwegian 22-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 22-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 22-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 22-06-2023
Patient Information leaflet Patient Information leaflet Croatian 22-06-2023
Public Assessment Report Public Assessment Report Croatian 07-09-2021

Search alerts related to this product